Keros TherapeuticsKROS +5.47%30 OCF Yield % is -26.34 as of Jun. 27, 2026. GuruFocus rates KROS with a GF Score™ of 30/100. The stock has 3 warning signs investors should review. Among 1,419 Biotechnology companies, Keros Therapeutics ranks worse than 73.93% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Keros Therapeutics OCF Yield % Related Terms
Keros Therapeutics OCF Yield % Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Keros Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keros Therapeutics OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keros Therapeutics's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Keros Therapeutics's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keros Therapeutics (KROS) has a OCF Yield % of -26.34 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Keros Therapeutics and its competitors. According to the industry distribution chart, Keros Therapeutics ranks #1049 out of 1419 companies in the Biotechnology industry, placing it in the top 73.9%.
Is Keros Therapeutics' OCF Yield % too high?
Keros Therapeutics' current OCF Yield % is -26.34. Based on the distribution chart, Keros Therapeutics ranks #1049 out of 1419 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Keros Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' OCF Yield % compare to RNA and RNAC?
According to the Biotechnology industry distribution chart, Keros Therapeutics ranks #1049 out of 1419 companies for OCF Yield %. This places Keros Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current OCF Yield % is -26.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Keros Therapeutics (KROS) has a current OCF Yield % of -26.34. The current OCF Yield % is -26.34. Keros Therapeutics' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current OCF Yield % is -26.34 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
30GF Score
Get the complete analysis for KROS
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
